ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy

Resistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance that do not imply mutations in BCR/ABL have been also described. In the present rep...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Aceves-Luquero, Clara I., Agarwal, Anupriya, Callejas-Valera, Juan L., Arias-González, Laura, Esparís-Ogando, Azucena, del Peso Ovalle, Luis, Bellón-Echeverria, Itxaso, de la Cruz-Morcillo, Miguel A., Galán Moya, Eva M., Gimeno, Inmaculada Moreno, Gómez, Juan C., Deininger, Michael W., Pandiella, Atanasio, Prieto, Ricardo Sánchez
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2009
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2699476/
https://ncbi.nlm.nih.gov/pubmed/19568437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0006124
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki